NCT05621070View on ClinicalTrials.gov

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

582

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

September 23, 2024

Study Completion Date

September 30, 2024

Conditions
Primary Hypercholesterolaemia and Mixed Dyslipidemia
Interventions
DRUG

JS002

JS002 will be administered per auto-injector. Participants will receive JS002 every 2 weeks subcutaneously.

DRUG

JS002

JS002 will be administered per auto-injector. Participants will receive JS002 every 4 weeks subcutaneously.

DRUG

Placebo

Placebo will be administered per auto-injector. Participants will receive placebo every 2 weeks subcutaneously.

DRUG

Placebo

Placebo will be administered per auto-injector. Participants will receive placebo every 4 weeks subcutaneously.

Trial Locations (1)

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER